A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

Phase 1

Recruiting

• Conditions: Non Small Cell Lung Cancer; Melanoma; Cervical Carcinoma
• Interventions: Drug: Autologous tumor infiltrating lymphocytes (TILs)

• Registration Number: NCT05366478
• Lead Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd.

Brief Summary

This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.

Detailed Description

This is an investigator initiated , single-arm, open-label ,exploratory study of LM103 Injection in patients with advanced solid tumors. Expanded TILs will be transferred to the patient after chemotherapy with cyclophosphamide and fludarabine. LM103 will be administered as a single dose on day 1. TIL transfer will be combined with IL-2 treatment. This study is planned to enroll 9-15 patients with advanced solid tumors.

Study Timeline

• Study First Submitted: 2022-05-05
• Study First Submitted QC: 2022-05-05
• Study First Posted: 2022-05-09
• Study Start: 2022-05-30
• Status Verified: 2022-08
• Last Update Submitted: 2022-08-01
• Last Update Posted: 2022-08-02
• Primary Completion: 2024-05-30
• Study Completion: 2029-05-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. AJCC (V8) stage III or IV melanoma, non-small cell lung cancer, cervical cancer and other solid tumors (confirmed by histology) for which existing treatment is ineffective or without standard treatment;

2. The patient has residual lesions that can be used for surgical resection (>1.5cm3) or biopsy (>1.5cm3) and measurable after resection for TIL collection and efficacy evaluation;

3. Laboratory inspection index requirements:

   • Blood routine: lymphocyte ratio > 20%; neutrophil count > 1.0 × 10^9/L; white blood cells > 3.0 × 10^9/L; platelets > 100 × 10^9/L; hemoglobin > 80 g/ L;
   • Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ upper limit of normal x 2.5, if there is liver metastasis ≤ upper limit of normal x 5; alkaline phosphatase (ALP) ≤ upper limit of normal x 2.5; total gallbladder Red pigment (TBIL)≤normal upper limit×1.5;
   • Renal function: urea ≤ upper limit of normal × 1.5; creatinine (Cr) ≤ upper limit of normal × 1.5;

4. Left ventricular ejection fraction (LVEF) ≥ 50%;

5. ECOG physical condition is 0 or 1;

6. The expected survival time is more than 3 months;

Exclusion Criteria

1. Suffering from active or previous autoimmune diseases ;
2. Severe liver and kidney dysfunction, severe heart disease, coagulation dysfunction, and hematopoietic dysfunction;
3. Combined with severe infection or persistent infection and cannot be effectively controlled;
4. Central nervous system metastasis and/or cancerous meningitis;
5. With uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage;
6. Requires systemic steroid therapy;
7. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HbcAb); positive for hepatitis C virus (HCV) antibody; positive for human immunodeficiency virus (HIV) antibody; positive for syphilis;

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Autologous tumor infiltrating lymphocytes (TILs)	Autologous tumor infiltrating lymphocytes (TILs)	In vitro expanded autologous TILs will be infused i.v. to patients with advanced solid tumors

Primary Outcome Measures

Name	Time	Method
Incidence and severity of adverse events (AEs)	Up to 1 years	Adverse events are graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Objective Response	Up to 2 years	Participants displaying objective response associated with the treatment regimen per Response Evaluation Criteria in Solid Tumors (RECIST v.1.1). The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.
Disease Control Rate (DCR）	Up to 2 years	Percentage of patients that meet CR, PR and SD criteria set in this study according to RECIST v1.1：
Progression-Free Survival (PFS)	Up to 2 years	The time length between TIL infusion and confirmed subsequent disease progression according to RECIST 1.1
The changes of the immunoreactivity during treatment	Up to 2 years	The changes from baseline of systemic immune Response markers: peripheral blood lymphocyte subtypes counts, cytokine, antigen-specific T-lymphocytes

Trial Locations

Locations (1)

Tianjin Beichen Hospital; 🇨🇳 Tianjin, China